🧩 NAC Aspergillosis Research Digest — Focus: Chronic Aspergillosis (October 2025: week 42)

🧬 Focus Review — Chronic Aspergillosis (October 2025)

Here are peer-reviewed papers on chronic aspergillosis published in the last month:

1. Improving Diagnostic Sensitivity Using Species-Specific IgG (Sep 2025)

• This study investigated better blood tests to diagnose CPA by measuring IgG antibodies not just to Aspergillus fumigatus but also to other common Aspergillus species.

• They found adding antibodies against non-fumigatus species identified more CPA cases that would have been missed by the standard A. fumigatus test alone.

• The treatment results were similar regardless of which Aspergillus species was involved.

• This means broader antibody testing improves diagnosis without changing expected outcomes.

• Read full paper on PubMed

2. Prevalence and Impact of Bacterial Co-infections in CPA (April 2025)

• This study looked at how often bacterial infections occur alongside CPA and their effect on patients.

• About 21% of CPA patients had bacterial co-infections.

• However, having a bacterial co-infection did not significantly change mortality rates compared to those without.

• This highlights the need to assess for bacteria but suggests it may not worsen long-term outcomes.

• Read full paper on PMC

3. Non-invasive Monitoring Using Serology and HRCT Imaging (June 2025)

• Researchers combined blood antibody tests and high-resolution chest CT scans to identify active Aspergillus infections in chronic lung disease patients.

• This method distinguished active infections from colonization without invasive procedures.

• It supports using combined non-invasive tests to decide who needs further invasive diagnostics or antifungal treatment.

• This approach helps avoid unnecessary treatments and invasive tests.

• Read full paper on Frontiers

In short: these studies improve how doctors diagnose and monitor CPA — by expanding antibody testing beyond classic targets, recognizing the role but limited impact of bacterial co-infections, and using combined non-invasive testing strategies to guide management safely and effectively.